Safety and effectiveness in switching from reference to biosimilar rituximab in rheumatoid arthritis patients: real world experience from a single Italian rheumatology centre

Clin Exp Rheumatol. 2021 Sep-Oct;39(5):1147-1148. doi: 10.55563/clinexprheumatol/uu34os. Epub 2021 Jun 25.

Authors

Fabio Cacciapaglia¹, Daniela Renna¹, Marco Fornaro¹, Vincenzo Venerito¹, Giuseppe Lopalco¹, Florenzo Iannone²

Affiliations

¹ Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), University of Bari Aldo Moro, Bari, Italy.
² Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), University of Bari Aldo Moro, Italy. florenzo.iannone@uniba.it.

PMID: 34251300
DOI: 10.55563/clinexprheumatol/uu34os

No abstract available

Publication types

Letter

MeSH terms

Antirheumatic Agents* / adverse effects
Arthritis, Rheumatoid* / diagnosis
Arthritis, Rheumatoid* / drug therapy
Biosimilar Pharmaceuticals* / adverse effects
Humans
Italy
Rheumatology*
Rituximab / adverse effects
Treatment Outcome

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Rituximab